MCID: SWN001
MIFTS: 39

Swine Influenza

Categories: Infectious diseases, Respiratory diseases

Aliases & Classifications for Swine Influenza

MalaCards integrated aliases for Swine Influenza:

Name: Swine Influenza 12 76 55 3 15 73
Influenza Due to Influenza a Virus Subtype H1n1 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050211

Summaries for Swine Influenza

CDC : 3 Swine influenza is a respiratory disease of pigs caused by type A influenza viruses that regularly cause outbreaks of influenza in pigs. Influenza viruses that commonly circulate in swine are called “swine influenza viruses” or “swine flu viruses.” Like human influenza viruses, there are different subtypes and strains of swine influenza viruses. The main swine influenza viruses circulating in U.S. pigs in recent years have been, swine triple reassortant (tr) H1N1 influenza virus, trH3N2 virus, and trH1N2 virus.

MalaCards based summary : Swine Influenza, also known as influenza due to influenza a virus subtype h1n1, is related to avian influenza and newcastle disease, and has symptoms including fever, vomiting and diarrhea. An important gene associated with Swine Influenza is GP2 (Glycoprotein 2). The drugs Vitamin A and Vitamin C have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and t cells.

Disease Ontology : 12 An influenza that results in infection located in respiratory tract of pigs and humans, has material basis in Influenza C virus, or has material basis in Influenza A virus subtypes (H1N1, H1N2, H3N1, H3N2, and H2N3), which are transmitted by direct contact with infected pigs. The infection in humans has symptom fever, has symptom lethargy, has symptom lack of appetite, has symptom coughing, has symptom runny nose, has symptom sore throat, has symptom nausea, has symptom vomiting, and has symptom diarrhea.

Wikipedia : 76 Swine influenza is an infection caused by any one of several types of swine influenza viruses. Swine... more...

Related Diseases for Swine Influenza

Diseases related to Swine Influenza via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 35)
# Related Disease Score Top Affiliating Genes
1 avian influenza 30.2 HAS1 TNF
2 newcastle disease 30.0 NEU1 TNF
3 influenza 11.3
4 pneumonia 10.5
5 viral infectious disease 10.5
6 foodborne botulism 10.0 GP2 HAS1
7 multiple sclerosis 10.0
8 bacterial pneumonia 10.0
9 respiratory system disease 10.0 HAS1 TNF
10 systemic lupus erythematosus 10.0
11 legionnaire disease 10.0
12 legionnaires' disease 10.0
13 legionellosis 10.0
14 respiratory failure 10.0
15 lymphopenia 10.0
16 appendicitis 10.0
17 lupus erythematosus 10.0
18 narcolepsy 10.0
19 dysostosis 9.9 NEU1 POLR1A
20 rheumatoid arthritis 9.8
21 myocardial infarction 9.8
22 arthritis 9.8
23 thrombocytopenia 9.8
24 mumps 9.8
25 vaccinia 9.8
26 plague 9.8
27 mouth disease 9.8
28 acute disseminated encephalomyelitis 9.8
29 myocarditis 9.8
30 chronic fatigue syndrome 9.8
31 neuropathy 9.8
32 smallpox 9.8
33 parainfluenza virus type 3 9.8
34 virus associated hemophagocytic syndrome 9.8
35 hemophagocytic syndrome associated with an infection 9.8

Graphical network of the top 20 diseases related to Swine Influenza:



Diseases related to Swine Influenza

Symptoms & Phenotypes for Swine Influenza

Symptoms:

12
  • fever
  • vomiting
  • diarrhea
  • lethargy
  • nausea
  • coughing
  • sore throat
  • lack of appetite
  • runny nose

UMLS symptoms related to Swine Influenza:


fever, pruritus, snoring, coughing

Drugs & Therapeutics for Swine Influenza

Drugs for Swine Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
2
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
3
Lactitol Investigational Phase 4,Phase 2,Not Applicable 585-86-4 3871
4 retinol Phase 4
5 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
6 Retinol palmitate Phase 4
7 Antiviral Agents Phase 4,Phase 3,Phase 2,Not Applicable
8 Antipyretics Phase 4
9 Trace Elements Phase 4
10 Antioxidants Phase 4
11 Micronutrients Phase 4
12 Vitamins Phase 4
13 Protective Agents Phase 4
14 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Antibodies Phase 4,Phase 2,Phase 1,Not Applicable
17 Immunoglobulins Phase 4,Phase 2,Phase 1,Not Applicable
18 MF59 oil emulsion Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Immunosuppressive Agents Phase 4
20 Hemagglutinins Phase 4,Phase 2,Phase 1
21
Oseltamivir Approved Phase 3,Phase 2,Not Applicable 204255-11-8, 196618-13-0 65028
22
Zanamivir Approved, Investigational Phase 3,Phase 2 139110-80-8 60855
23
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
24
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
25 Adjuvants, Immunologic Phase 2, Phase 3,Phase 3,Not Applicable
26 Anti-Inflammatory Agents Phase 3,Phase 2
27 Hydrocortisone-17-butyrate Phase 3
28 Cortisol succinate Phase 3
29 Hydrocortisone 17-butyrate 21-propionate Phase 3
30
Thymalfasin Investigational Phase 2 62304-98-7
31 Antibodies, Monoclonal Phase 2
32 Pharmaceutical Solutions Phase 2
33 Agglutinins Phase 1, Phase 2
34 Antibiotics, Antitubercular Phase 2
35 Anti-Bacterial Agents Phase 2
36 gamma-Globulins Phase 2
37 Immunoglobulins, Intravenous Phase 2
38 Rho(D) Immune Globulin Phase 2
39 Hypolipidemic Agents Phase 2,Not Applicable
40 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2,Not Applicable
41 Anticholesteremic Agents Phase 2,Not Applicable
42 Lipid Regulating Agents Phase 2,Not Applicable
43 Antimetabolites Phase 2,Not Applicable
44 Calcium, Dietary Phase 2,Not Applicable
45 Rosuvastatin Calcium Phase 2,Not Applicable 147098-20-2
46
Aluminum sulfate Approved Phase 1 10043-01-3
47
Spiramycin Approved 24916-50-5
48
Levofloxacin Approved, Investigational 100986-85-4 149096
49
Ofloxacin Approved 82419-36-1 4583
50
Ceftriaxone Approved 73384-59-5 5479530 5361919

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A Unknown status NCT01127282 Phase 4 Vitamin (vitamin A 15 mg,C 500 mg, E 400IU);Placebo (digestive tablet)
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
4 Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects Completed NCT01069367 Phase 4
5 H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients Completed NCT01111162 Phase 4
6 A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines Completed NCT01004653 Phase 4
7 Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults Completed NCT01008137 Phase 4
8 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV Completed NCT01002040 Phase 4
9 Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients Completed NCT01022905 Phase 4
10 Safety of H1N1 Influenza Vaccination in Pregnant Women Completed NCT01842997 Phase 4
11 Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children Completed NCT01000831 Phase 4
12 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults Completed NCT01001026 Phase 4
13 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine Completed NCT01000584 Phase 4
14 Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects Completed NCT01079273 Phase 4
15 Vaccination Against Influenza in Autoimmune Diseases Completed NCT01065285 Phase 4
16 Phase IV Clinical Trial of an Influenza Split Vaccine Anflu Completed NCT00556062 Phase 4
17 Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine Completed NCT01023776 Phase 4
18 A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults Completed NCT00945893 Phase 4
19 A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age Completed NCT00946101 Phase 4
20 Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older Completed NCT01114620 Phase 4
21 A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season Completed NCT01457027 Phase 4
22 Direct and Indirect Protection by Influenza Vaccine Given to Children in India Completed NCT00934245 Phase 4
23 Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children Withdrawn NCT01097941 Phase 4
24 Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine Unknown status NCT01582633 Phase 2, Phase 3
25 Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month Unknown status NCT01040078 Phase 3
26 Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects Completed NCT01000207 Phase 2, Phase 3
27 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years) Completed NCT00972816 Phase 2, Phase 3
28 Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India Completed NCT01053143 Phase 3
29 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years) Completed NCT00973700 Phase 3
30 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults Completed NCT00973349 Phase 2, Phase 3
31 Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects Completed NCT00996138 Phase 2, Phase 3
32 Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection Completed NCT01032408 Phase 3
33 Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors Completed NCT01031719 Phase 3
34 Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults Completed NCT00989287 Phase 2, Phase 3
35 Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes Completed NCT00992511 Phase 3
36 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age Completed NCT00971906 Phase 3
37 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age Completed NCT00971542 Phase 3
38 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age Completed NCT00971100 Phase 3
39 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age Completed NCT00970177 Phase 3
40 Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza? Completed NCT01001325 Phase 3
41 Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus Completed NCT01032395 Phase 3
42 Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months Completed NCT00996307 Phase 2, Phase 3
43 Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age Completed NCT01051661 Phase 3
44 A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine Completed NCT01201902 Phase 3
45 A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection Terminated NCT00979667 Phase 3 Oseltamivir;Zanamivir;Placebo of Oseltamivir
46 Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu Terminated NCT01014364 Phase 3 hydrocortisone;isotonic saline
47 Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients Unknown status NCT01055990 Phase 2
48 A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months Completed NCT00956046 Phase 2
49 A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults Completed NCT01089660 Phase 2
50 A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years Completed NCT00956202 Phase 2

Search NIH Clinical Center for Swine Influenza

Genetic Tests for Swine Influenza

Anatomical Context for Swine Influenza

MalaCards organs/tissues related to Swine Influenza:

41
Testes, Lung, T Cells, Lymph Node, Neutrophil, Brain, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Swine Influenza:

19
Respiratory Tract Of Pigs

Publications for Swine Influenza

Articles related to Swine Influenza:

(show top 50) (show all 807)
# Title Authors Year
1
Effects of the S42 residue of the H1N1 swine influenza virus NS1 protein on interferon responses and virus replication. ( 29587786 )
2018
2
Emergence of Eurasian Avian-Like Swine Influenza A (H1N1) Virus from an Adult Case in Fujian Province, China. ( 29797225 )
2018
3
Isolation and molecular characterization of an H5N1 swine influenza virus in China in 2015. ( 29164401 )
2018
4
Effects of Isatis root polysaccharide in mice infected with H3N2 swine influenza virus. ( 29890386 )
2018
5
Swine influenza viruses in Northern Vietnam in 2013-2014. ( 29967457 )
2018
6
Regional patterns of genetic diversity in swine influenza A viruses in the United States from 2010 to 2016. ( 29624873 )
2018
7
Molecular subtyping of European swine influenza viruses and scaling to high-throughput analysis. ( 29316958 )
2018
8
Monoclonal Antibody Against HA Protein of the European Avian-Like H1N1 Swine Influenza Virus. ( 29630477 )
2018
9
Evidence of infection with avian, human, and swine influenza viruses in pigs in Cairo, Egypt. ( 29075888 )
2018
10
Substitution of D701N in the PB2 protein could enhance the viral replication and pathogenicity of Eurasian avian-like H1N1 swine influenza viruses. ( 29717109 )
2018
11
Maternally-derived antibodies do not inhibit swine influenza virus replication in piglets but decrease excreted virus infectivity and impair post-infectious immune responses. ( 29519509 )
2018
12
Molecular evolution of H1N1 swine influenza in Guangdong, China, 2016-2017. ( 29477550 )
2018
13
Intradermal immunization with inactivated swine influenza virus and adjuvant polydi(sodium carboxylatoethylphenoxy)phosphazene (PCEP) induced humoral and cell-mediated immunity and reduced lung viral titres in pigs. ( 29454517 )
2018
14
Subtyping of Swine Influenza Viruses Using a High-Throughput Real-Time PCR Platform. ( 29872645 )
2018
15
A Naturally Occurring Deletion in the Effector Domain of H5N1 Swine Influenza Virus Nonstructural Protein 1 Regulates Viral Fitness and Host Innate Immunity. ( 29563291 )
2018
16
Corrigendum to &amp;quot;Molecular epidemiology of swine influenza A viruses in the Southeastern United States, highlights regional differences in circulating strains'' [Vet. Microbiol. 211 (2017) 174-179]. ( 29274732 )
2018
17
Tissue tropisms opt for transmissible reassortants during avian and swine influenza A virus co-infection in swine. ( 30507946 )
2018
18
Plasticity of amino acid residue 145 near the receptor binding site of H3 swine influenza A viruses and its impact on receptor binding and antibody recognition. ( 30355680 )
2018
19
Eurasian avian-like swine influenza A viruses escape human MxA restriction by distinct mutations in their nucleoprotein. ( 30355693 )
2018
20
Detailed mapping of the linear B Cell epitopes of the hemagglutinin (HA) protein of swine influenza virus. ( 30029012 )
2018
21
Infection of novel reassortant H1N2 and H3N2 swine influenza A viruses in the guinea pig model. ( 30053826 )
2018
22
Protective efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the European Avian-like H1N1 swine influenza virus in mice and pigs. ( 30080677 )
2018
23
Swine Influenza Virus Induces RIPK1/DRP1-Mediated Interleukin-1 Beta Production. ( 30096906 )
2018
24
Genome Sequence of an Unusual Reassortant H1N1 Swine Influenza Virus Isolated from a Pig in Russia, 2016. ( 28883131 )
2017
25
Coinfection modulates inflammatory responses, clinical outcome and pathogen load of H1N1 swine influenza virus and Haemophilus parasuis infections in pigs. ( 29202835 )
2017
26
Letter to the editor: Just a coincidence? Two severe human cases due to swine influenza (SIV) A(H1N1)v in Europe, October 2016. ( 28300531 )
2017
27
Kaempferol ameliorates H9N2 swine influenza virus-induced acute lung injury by inactivation of TLR4/MyD88-mediated NF-I_B and MAPK signaling pathways. ( 28262619 )
2017
28
Pathogenicity and transmission of a swine influenza A(H6N6) virus. ( 28400591 )
2017
29
Genetic analysis of human and swine influenza A viruses isolated in Northern Italy during 2010-2015. ( 28791803 )
2017
30
Hidden authority study data have come to light: besides narcolepsy, the swine influenza vaccine Pandemrix caused type 1 diabetes. ( 27995691 )
2017
31
Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. ( 28057521 )
2017
32
Estimation of the transmission parameters for swine influenza and porcine reproductive and respiratory syndrome viruses in pigs from weaning to slaughter under natural conditions. ( 28237230 )
2017
33
The PB2-K627E mutation attenuates H3N2 swine influenza virus in cultured cells and in mice. ( 29175013 )
2017
34
Influence of microclimate conditions on the cumulative exposure of nursery pigs to swine influenza A viruses. ( 28940764 )
2017
35
Feral Swine in the United States Have Been Exposed to both Avian and Swine Influenza A Viruses. ( 28733290 )
2017
36
Pig Lung Immune Cytokine Response to the Swine Influenza Virus and the <i>Actinobacillus Pleuropneumoniae</i> Infection. ( 29978082 )
2017
37
Harnessing Local Immunity for an Effective Universal Swine Influenza Vaccine. ( 28475122 )
2017
38
Protective efficacy of a virus-vectored multi-component vaccine against porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 and swine influenza virus. ( 29091579 )
2017
39
Molecular epidemiology of swine influenza A viruses in the Southeastern United States, highlights regional differences in circulating strains. ( 29102115 )
2017
40
Pathogenicity and transmission of triple reassortant H3N2 swine influenza A viruses is attenuated following Turkey embryo propagation. ( 28284612 )
2017
41
Epigallocatechin-3-gallate inhibits TLR4 signaling through the 67-kDa laminin receptor and effectively alleviates acute lung injury induced by H9N2 swine influenza virus. ( 28858723 )
2017
42
Comparison of mono- and co-infection by swine influenza A viruses and porcine respiratory coronavirus in porcine precision-cut lung slices. ( 28779714 )
2017
43
PA-X protein decreases replication and pathogenicity of swine influenza virus in cultured cells and mouse models. ( 28622865 )
2017
44
Authors' reply: Two severe human cases due to swine influenza A (H1N1)v in October 2016 in Europe were chronologic coincident yet distinct events. ( 28300530 )
2017
45
Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice. ( 28941982 )
2017
46
Protection of human influenza vaccines against a reassortant swine influenza virus of pandemic H1N1 origin using a pig model. ( 28267619 )
2017
47
Kinetics of single and dual infection of pigs with swine influenza virus and Actinobacillus pleuropneumoniae. ( 28284596 )
2017
48
Detection of Antigenic Variants of Subtype H3 Swine Influenza A Viruses from Clinical Samples. ( 28077698 )
2017
49
Swine Influenza Virus (H1N2) Characterization and Transmission in Ferrets, Chile. ( 28098524 )
2017
50
Pathogenicity of modified bat influenza virus with different M genes and its reassortment potential with swine influenza A virus. ( 28100299 )
2017

Variations for Swine Influenza

Expression for Swine Influenza

Search GEO for disease gene expression data for Swine Influenza.

Pathways for Swine Influenza

GO Terms for Swine Influenza

Biological processes related to Swine Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of insulin secretion GO:0050796 8.96 SLC8B1 TNF
2 animal organ morphogenesis GO:0009887 8.8 FGD1 TNF TREH

Molecular functions related to Swine Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity, acting on glycosyl bonds GO:0016798 8.62 NEU1 TREH

Sources for Swine Influenza

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....